Sierra Health and Life targeted neurogenetic coverage

Coverage Criteria for Genetic Testing — Neurological Disorders

Covered — Multi-gene Targeted Panels (≥5 genes)

Multi-gene Targeted Panel testing (five or more genes) for neurological disorders is proven and medically necessary when ALL of the following are met:

Eligibility for covered Targeted Panel: The individual to be tested displays signs or symptoms of a heritable neurological disorder and the results are expected to directly impact medical management of that disorder.

supported by policy coverage rationale

Ordering clinician: The test is ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist.

required specialty ordering

Intended purpose: The test is intended to establish a genetic cause for any one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; or Muscular dystrophy.

listed target indications

Not medically necessary — Comprehensive Panels

Not covered — Comprehensive Panels: Comprehensive Panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary due to insufficient evidence of efficacy.

policy stance against broad/comprehensive panels

Medically Necessary Genetic Testing

Covered when ALL of the following are met

Clinical indication and specialty guidance: Testing is ordered for diagnosis or classification of suspected hereditary neuromuscular or neurological disease and is guided by clinical phenotype, inheritance pattern, and electrodiagnostic features as recommended by professional guidelines.

Supported by AAN/AANEM guidance

Test selection rationale: The chosen test (targeted panel, copy‑number/ CNV analysis, repeat expansion testing, or WES when appropriate) is appropriate for the phenotype and includes documentation of prior relevant testing or an explanation why previous tests were insufficient.

Supported by studies showing phenotype‑guided panels and CNV/repeat analysis increase yield

Laboratory standards: Testing is performed in a CLIA‑certified laboratory with appropriate analytic validation and reporting standards; FDA clearance/approval is informational and not by itself a basis for coverage.

Laboratory regulation referenced (CLIA); FDA informational only

Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are not covered by this policy; they are addressed in the separate Medical Policy titled Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions). Additionally, the policy distinguishes between Targeted Panels (condition- or phenotype-directed multi-gene assays) and broad/comprehensive multi-category panels, stating that Comprehensive Panel tests intended to evaluate multiple genes across distinct neurological disorder categories are unproven and not medically necessary due to insufficient evidence of efficacy.

The FDA section in this policy is provided for informational purposes only: FDA approval alone is not a basis for coverage. Laboratories that perform genetic tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA); coverage determinations should not rely solely on FDA clearance or approval.

This Medical Policy is intended to assist in interpreting UnitedHealthcare standard benefit plans and is provided for informational purposes. It does not constitute medical advice. For any member, the applicable member-specific benefit plan document and any federal or state mandates govern coverage decisions; in the event of a conflict, the member-specific plan document controls.

Comprehensive Panel tests that span multiple, clinically distinct neurological disorder categories (broad/comprehensive panels) are considered unproven and not medically necessary. The policy rationale notes that genotype–phenotype correlations typically support targeted, phenotype-directed testing, while comprehensive panels include genes unrelated to the presenting phenotype and lack sufficient evidence of clinical utility.

Indications Considered Medically Necessary

Establishing a genetic cause for congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, or muscular dystrophy.

Covered indication: Establishing a genetic cause for congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, or muscular dystrophy.

Covered when targeted panel (≥5 genes) is ordered by/with specified specialists and results expected to directly impact management.

Suspected inherited neuromuscular disorders (e.g., myopathies, muscular dystrophies, peripheral neuropathies, SMA) where phenotype or testing rationale supports targeted panel or broader sequencing.

Suspected inherited neuromuscular disorders (e.g., myopathies, muscular dystrophies, peripheral neuropathies, spinal muscular atrophy) where clinical phenotype, inheritance pattern, or electrodiagnostic features support use of a targeted multi‑gene panel (≥5 genes) or justify broader sequencing approaches when documented rationale and prior testing are provided.

Higher diagnostic yields reported for specific phenotypes; include SMN1/SMN2 testing where appropriate

Coding and Billing

Applicable CPT/PLA/Unlisted codesmixed

0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
81448	Hereditary peripheral neuropathies (e.g., Charcot‑Marie‑Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (e.g., BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1).
81479	Unlisted molecular pathology procedure

Informational references (no explicit codes listed in this document window)mixed

No codes listed

inv-10: Minimum genes in panel

Minimum panel size>= 5 genes

Supporting code noteCPT 81448 description requires sequencing of at least 5 peripheral neuropathy-related genes

Policy coverage tie-inMulti-gene Targeted Panel testing (five or more genes) is medically necessary when clinical criteria are met

inv-11: Diagnostic yield by phenotype

Example diagnostic yieldAtaxia or spastic paraparesis: 19% (Schuermans et al. 2023)

Overall cohort yieldGenetic diagnosis identified in 10% of total cases in the study cohort of 1,411 individuals

Provider Actions, Authorization, and Documentation

Documentation Required

Check Member Plan and Mandates

Before ordering genetic testing, verify the member-specific benefit plan document and any applicable federal or state mandates, as plan terms or mandates may alter coverage. In the event of a conflict, the member-specific benefit plan governs.

Check member-specific benefit plan document and applicable federal/state mandates prior to use.
Member-specific plan governs in case of conflict.

Note

Preferred Testing Approach

This policy favors a targeted, phenotype-directed testing strategy. Prefer condition- or phenotype‑directed Multi-Gene Targeted Panels (≥5 genes) ordered by appropriate specialists over broad Comprehensive Panels when clinical criteria are met. Algorithmic or stepwise testing that begins with the most likely, common genetic causes is the preferred approach.

Preferred approach: Targeted Panels (condition- or phenotype-directed) over Comprehensive Panels.
Algorithmic or stepwise testing is preferred; start with tests most likely to explain the phenotype.

Tests and Uses Not Covered

Not covered: Comprehensive panels evaluating genes across multiple distinct neurological disorder categories are unproven and considered not medically necessary. The policy emphasizes the higher clinical utility of phenotype-directed targeted panels and explains that existing evidence does not support routine use of broad, multi-category panels for neurologic genetic evaluation.

The policy reiterates that FDA approval or clearance alone is not sufficient to determine coverage. This FDA-related information is included for reference only; laboratories are regulated under CLIA and appropriate laboratory accreditation and analytic validation are required for testing.

Eligibility Requirements

No top-level eligibility requirement nodes are defined in this section of the policy summary. Refer to the coverage criteria and covered indications sections for required clinical features, ordering clinician qualifications, and specific test selection guidance.

No additional eligibility requirement nodes are specified in this inventory placeholder. Coverage decisions depend on meeting the clinical criteria and documentation described elsewhere in the policy.

This placeholder indicates no separate eligibility requirement entries in the extracted inventory for this policy window. See covered indications and prior authorization guidance for applicable requirements.

Definitions

inv-25: Targeted Panel

DefinitionTargeted Panel: a curated assay that simultaneously tests more than one gene associated with a condition or symptom; may target genes for one specific condition or multiple genes associated with a symptom or non-specific presentation (Rehder et al., 2021)

ScopeDesigned to evaluate genes relevant to a single condition or closely related phenotype(s)

Policy preferencePolicy favors targeted (condition-/phenotype-directed) panels over broad/comprehensive panels when clinical criteria are met

inv-26: Comprehensive Panel

DefinitionComprehensive Panel: an assay that simultaneously tests more than one gene associated with a variety of conditions, symptoms, or non-overlapping clinical presentations (Rehder et al., 2021)

Policy stance

Background and Evidence Summary

Neurological disorders encompass a range of neurodegenerative and neuromuscular conditions, many of which have genetic causes. Genetic testing options range from single-variant assays through Targeted multi-gene panels to broader approaches such as WES/WGS. More than 500 genes have been associated with neuromuscular disorders, and genotype–phenotype correlations often support a phenotype-first testing strategy; genome-scale testing may be considered in complex cases or after unrevealing targeted workups.

Policy Revision History

2026-01-01template_update_and_consolidationLatest

Template update and consolidation to create a shared policy version applicable to Oxford plan membership; previous policy versions 2025T0598M and DIAGNOSTIC 107.10 were archived.

OpenPayer

Genetic Testing for Neurological Disorders